# DESCRIPTION

## FIELD OF THE INVENTION

- introduce bacterial infections
- motivate need for new antibiotics
- describe limitations of current antibiotics
- introduce protein aggregation concept
- explain bacterial proteostasis
- introduce novel designer antibiotics paradigm

## SUMMARY OF THE INVENTION

- summarize invention of novel antimicrobial peptides

## DETAILED DESCRIPTION TO THE INVENTION

- define terms used in the invention
- describe the scope of the invention
- provide definitions for terms of the art
- introduce the concept of "about"
- define "polypeptide" and "peptide"
- define "recombinant polypeptide"
- define "expression" and "gene expression"
- define "recombinant host cell"
- define "modulate" and "modulation"
- define "enhance" and "increase"
- define "inhibit" and "reduce"
- define "contact"
- define "therapeutically effective" amount
- define "treat" and "treatment of"
- define "functional" peptide
- describe conservative amino acid substitutions
- introduce the novel designer antibiotics paradigm
- describe the mode of action of colpeptin1
- describe the advantages of the invention
- provide a first aspect of the invention
- describe the structure of the peptide
- provide a related aspect of the invention
- provide peptidomimetic
- describe embodiments of peptide or peptidomimetic
- describe uses of peptide or peptidomimetic
- describe structure of anti-bacterial peptide
- describe embodiments of anti-bacterial peptide
- describe uses of anti-bacterial peptide
- describe structure of peptide with gatekeepers and APR
- describe embodiments of peptide with gatekeepers and APR
- describe uses of peptide with gatekeepers and APR
- describe structure of peptide with gatekeepers, APR, and linker
- describe embodiments of peptide with gatekeepers, APR, and linker
- describe uses of peptide with gatekeepers, APR, and linker
- describe sequences of peptides
- describe structure of peptide with gatekeepers, X1-X7, and linker
- describe embodiments of peptide with gatekeepers, X1-X7, and linker
- define linker moieties
- describe linker length and composition
- introduce peptide structure
- describe gatekeeper amino acids
- describe X1-X7 residues
- describe Zi linker
- provide peptide embodiments
- describe Colpeptin1 sequence
- introduce X1, X3, X5, and X7 residue variants
- describe X2, X4, and X6 residue variants
- provide alanine analogues
- provide arginine analogues
- provide glycine analogues
- provide leucine analogues
- provide valine analogues
- provide lysine analogues
- provide ornithine analogues
- provide proline analogues
- describe linker composition
- conclude peptide embodiments
- define cyclic peptide structure
- introduce detectable label
- describe isotopically labelled peptides
- motivate half-life extension
- motivate solubility increase
- describe fusion to other moieties
- introduce D-alanine at termini
- describe use as medicament
- describe use as anti-bacterial agent
- describe use to treat bacterial strains
- describe use as diagnostic agent
- describe pharmaceutical composition
- outline method to produce anti-bacterial peptide
- describe identifying APR sequences
- discuss peptide modifications and substitutions

### Administration of Peptides of the Inventionâ€”Pharmaceutical Compositions Comprising Peptides of the Invention

- introduce administration methods
- describe pharmaceutical carriers
- outline routes of administration
- discuss dosage requirements
- describe modified terminus peptides
- outline non-natural amino acid peptides
- discuss concurrent delivery with other agents
- describe kit composition
- outline pharmaceutical formulations
- discuss methods of administration
- describe formulation for injection
- outline oral administration formulations
- describe topical and transdermal formulations
- discuss nasal and pulmonary administration
- outline liposomal formulations

### Synthesis of Peptides

- introduce peptide synthesis methods
- describe solid phase synthesis process
- describe liquid phase synthesis process
- explain condensation of partial peptide or amino acid
- describe eliminating protecting group
- list examples of condensing methods and eliminating methods
- describe purification and isolation of peptides
- explain conversion of peptide to suitable salt
- list examples of activation reagents for peptide synthesis
- describe reaction conditions for peptide synthesis
- explain protecting groups for amino acids
- describe activated carboxyl groups and amino groups
- explain removing protecting groups
- define peptide structure
- specify gatekeeper amino acids
- specify X1-X7 amino acids
- specify Zi linker
- define peptide variants
- define cyclic peptide
- define peptidomimetic
- define labeled peptide
- define half-life extended peptide
- define solubility-enhanced peptide
- define D-alanine-containing peptide
- define pharmaceutical composition
- define method to produce anti-bacterial peptide
- define alternative peptide structure
- disclaim limitations

### Examples

- design aggregating peptides
- identify aggregation prone regions (APRs) in E. coli proteome
- generate tandem repeat design of APRs
- synthesize and purify peptides
- test peptide activity on E. coli growth
- rank APRs by frequency of occurrence
- select top 75 APRs for further analysis
- mutate residues to modulate aggregation propensity
- measure peptide activity at different concentrations
- analyze peptide activity using CAMP software
- select active peptides for further characterization
- resynthesize and HPLC purify selected peptides
- confirm MIC and MBC values of purified peptides
- analyze rate of peptide bactericidal activity
- evaluate peptide specificity using hemolytic activity assay
- test peptide activity against various bacterial strains
- correlate peptide activity with sequence conservation of HcaB protein
- analyze peptide aggregation using ESI-IMS-MS and DLS
- study peptide solubility over time using ultracentrifugation
- analyze secondary structure content using FTIR
- test peptide activity in a bladder infection model
- evaluate peptide uptake and IB formation in E. coli
- study the composition of IBs purified from E. coli

## Materials and Methods

### 1. Bio-Informatics Analysis

- perform bio-informatics analysis

### 2. Peptide Synthesis

- synthesize peptides

### 3. Bacterial Strains and Growth Conditions

- cultivate bacterial strains

### 4. MIC Determination

- determine MICs

### 5. Antibody and Antibiotic Product Codes

- list product codes

### 6. Biophysical Characterization

- perform biophysical characterization

### 7. Time Killing Kinetic Assay

- perform time-kill kinetics study

### 8. Multistep Resistance Development Study

- evaluate resistance development

### 9. Scanning Electron Microscopy

- prepare E. coli O157 bacteria
- fix bacteria with glutaraldehyde
- postfix with osmium tetroxide
- dehydrate with ethanol series
- dry with hexamethyldisilazane
- mount on specimen stubs
- sputter coat with gold
- use SEM-FEG microscope
- set accelerating voltage to 30 kV
- capture images
- repeat for control group
- treat bacteria with peptides
- fix bacteria with glutaraldehyde
- postfix with osmium tetroxide
- dehydrate with ethanol series
- dry with hexamethyldisilazane
- mount on specimen stubs
- sputter coat with gold
- use SEM-FEG microscope

